- Pluri to take advantage of it proprietary 3D technology platform To develop cell-based products for the coffee industry Under its new vertical business Pluriagetic
- the Growing fast $130 one billion Coffee industry He is in danger As global warming reduces the availability of land suitable for growing coffee By up to 50% by 2050
- CCompared to traditional methods of coffee production, multiple cCoffee based goodness Estimated by Reducing carbon footprint by scale downa job Water use by 98% Reducing growing areas by 95% (thus preventing deforestation)
Haifa, Israel, January 23, 2024 (GLOBE NEWSWIRE) — Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company that transforms cells into solutions that enhance the global well-being and sustainability company today announced that it has launched its cell-based coffee business. , an innovative product that will revolutionize the traditional coffee industry. Pluri's cell-based coffee product is designed to meet the growing global demand for sustainable, high-quality coffee when produced at scale.
Pluri is a pioneer in industrial-scale plant cell-based manufacturing solutions for the coffee industry, leveraging its 3D cell expansion technology to produce high-quality coffee under the company's new business, PluriAgtech. PluriAgtech aims to shape a brighter, greener future for agriculture by using cutting-edge cell technology to create more environmentally friendly alternatives to traditional farming methods.
cells Made to me Ground coffee
Cell-based frosted coffee
PluriAgtech's cell-based coffee was developed to deliver authentic coffee while solving key challenges faced by the industry. Compared to traditional methods of coffee production, Bluri cell-based coffee is expected to reduce water use by 98%. This innovation promises to address the decline in areas suitable for agriculture, which is expected to decrease by up to 50% by 2050. Reducing price instability in the traditional goods market; And reduce the environmental impact of coffee production, as current production methods have a high carbon footprint and upcoming regulations are expected to increase pressure on producers. While coffee production challenges remain, global demand for coffee is expected to triple by 2050.
Crystal's goal is to produce cell-based coffee as a new subsidiary focused on developing innovative products, technologies and intellectual property for the coffee industry. This planned new subsidiary will be led by Michal Ugulnik, a dynamic, results-oriented business leader. She has over 20 years of executive management experience in the pharmaceutical and energy sectors.
“We are uniquely positioned to transform the coffee industry with our sustainable cell-based coffee,” said Michal Ugolnik. “By harnessing the power of cutting-edge Pluri technology, we can create a brighter, more sustainable future for our planet. By putting innovation at the forefront, we can address some of the most pressing challenges facing the coffee industry.”
“We strongly believe in the potential of cell technology to make agriculture and food growing more productive and sustainable. Pluri's advanced agtech solutions have the potential to reduce the environmental footprint of traditional agricultural production. PluriAgtech can offer many Solutions ranging from products such as cell-based coffee to bioactive products in order to address the biggest challenges in agriculture. “We see great interest in developing additional cell-based products under the PluriAgtech segment from potential partners. “We are excited about the opportunities that cell-based coffee offers.”
To learn more about Pluri cell-based coffee, visit our website.
About Bluri Company
Blury is pushing the boundaries of science and engineering to create cell-based products for commercial use, and is a pioneer in the biotechnology revolution that advances global well-being and sustainability. The company's technology platform, a patented and validated state-of-the-art 3D cell expansion system, develops new cell-based solutions to a range of challenges – from medicine and climate change to food scarcity, animal cruelty and beyond. The Pluri method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food technology, agricultural and biotechnology and provides CDMO services. Pluri creates partnerships that leverage the company's 3D cell technology across various industries that require efficient, mass-produced cells. To learn more, visit us at www.pluri-biotech.com Or follow Pluri on LinkedIn and X (formerly known as Twitter).
Safe Harbor Statement
This press release contains forward-looking statements expressed or implied under the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. For example, Pluri uses forward-looking statements when it discusses the intended use of its 3D technology platform to develop cell-based products for the coffee industry within its new vertical business, PluriAgtech; Growth of the coffee industry. The potential benefits of PluriAgtech and its ability to address issues in the coffee market, as well as the environment; Its belief that the cell-based coffee product will revolutionize the traditional coffee industry and meet the growing global demand for sustainable, high-quality coffee on a large scale; PluriAgtech's goal is to shape a brighter, greener future for agriculture by using advanced cell technology to create more environmentally friendly alternatives to traditional farming methods; Blori's goal is to produce cell-based coffee as a new subsidiary focused on developing innovative products, technologies and intellectual property for the coffee industry; that its technology can create a brighter, more sustainable future for the planet; Its cooperation with current and potential strategic partners; Its goal is to develop cutting-edge products and technology; And its ability to face the biggest challenges in the field of agriculture. These forward-looking statements and their implications are based solely on the current expectations of Pluri's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in forward-looking statements about Pluri: changes in technology and market demands; Pluri may experience delays or obstacles in successfully launching and/or completing its proposed plans, including research and development; Its products may not be approved by regulatory bodies; Its technology may not be validated as it advances and its methods may not be accepted; may not be able to retain or attract key employees whose knowledge is essential to the development of its products; Unexpected scientific difficulties may develop during its operations. Their products may end up being more expensive than you expect; Results in the laboratory may not translate to equally good results in real-world settings; Patents may not be enough; Its products may harm recipients or consumers; Changes in legislation that have a negative impact; inability to develop and introduce new technologies, products and applications in a timely manner; Loss of market share and pressure on prices resulting from competition, which could cause actual results or performance of Pluri to differ materially from those projected in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri's reports filed from time to time with the Securities and Exchange Commission.
Media communication
Investors: investor.relations@pluri-biotech.com
Israeli media: Shashar Yantal shacharye@gitam.co.il
US Media: Brianna Ziegler at brianna@miller-ink.com
Images accompanying this advertisement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/31fa6b78-6ee7-444a-afe1-57f03f39c325
https://www.globenewswire.com/NewsRoom/AttachmentNg/e826ee11-8077-4840-8ef8-428e9cb724c4
